When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
After announcing a complete response in the first dose cohort of a Phase 1a/b AML study, shares of Aptose Biosciences rallied 66% on March 24th to close over $6.
This news is backed up by a preclinical study in which luxeptinib demonstrated 100% complete responses in the two highest dose cohorts of murine models.
With additional data expected in June from both its AML and CLL studies, Aptose merited further investigation.
A full investment analysis follows in the paragraphs below.